Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix LucentAD p-Tau 217

Quanterix has launched its LucentAD p-Tau 217 lab-developed test for assessing brain amyloid pathology in patients suspected of having Alzheimer's disease. The blood-based assay uses J&J Innovative Medicine's p-Tau 217 antibodies and Quanterix's Simoa immunoassay technology.